Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Gelsi Boyer, Véronique ^a,b,c   Brecqueville, Mandy ^a,b   Devillier, Raynier ^a,b   Murati, Anne ^a   Mozziconacci, Marie Joelle ^a   Birnbaum, Daniel ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

ASXL1; Gene mutations; Myeloid diseases

Indexed keywords

ASXL1 PROTEIN; ASXL2 PROTEIN; ASXL3 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ASXL1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BONE MARROW CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; FRAMESHIFT MUTATION; GENE DELETION; HUMAN; MALIGNANT MYELOID DISEASE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NONSENSE MUTATION; POLYCYTHEMIA VERA; PROTEIN FUNCTION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW; THROMBOCYTHEMIA; BIOLOGICAL MODEL; BONE MARROW DISEASE; CLASSIFICATION; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROGNOSIS;

BONE MARROW DISEASES; DNA MUTATIONAL ANALYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MODELS, BIOLOGICAL; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; REPRESSOR PROTEINS;

EID: 84858600403     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-12     Document Type: Review

References (53)

1. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Br J Haematol 2009 145 788 800 10.1111/j.1365-2141.2009.07697.x 19388938
2. The HARE-HTH and associated domains: Novel modules in the coordination of epigenetic DNA and protein modifications. Aravind L, Iyer LM, Cell Cycle 2012 11 1 119 131 10.4161/cc.11.1.18475 22186017
3. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW, Müller J, Nature 2010 465 243 247 10.1038/nature08966 20436459
4. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. Cho YS, Kim EJ, Park UH, Sin HS, Um SJ, J Biol Chem 2006 281 17588 17598 10.1074/jbc.M512616200 16606617 (Pubitemid 44035558)
5. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Hellström-Lindberg E, Cazzola M, Wainscoat JS, Leukemia 2010 24 1062 1065 10.1038/leu.2010.20 20182461
6. Silencing chromatin: comparing modes and mechanisms. Beisel C, Paro R, Nat Rev Genet 2011 12 123 135 21221116
7. ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. Abstract 405, ASH December 2011. Abdel-Wahab O, Adli M, Saunders L, Gao J, Shih AH, Pandey S, Jaffe J, Zhao X, Perna F, Carroll M, Melnick A, Nimer SD, Aifantis I, Bernstein B, Levine RL, Session: 603 Oncogenes and Tumor Suppressors: From Genomic-based Discovery to Functional Validation
8. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC, Nat Genet 2010 42 722 726 10.1038/ng.621 20601953
9. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH, Nat Genet 2010 42 665 667 10.1038/ng.620 20601954
10. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Brecqueville M, Cervera N, Adelaide J, Rey J, Carbucia N, Chaffanet M, Vey N, Murati A, Blood Cancer Journal 2011 1 33 10.1038/bcj.2011.31
11. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, Döhner K, Chase A, Cross NC, Blood 2012 119 1208 1213 10.1182/blood-2011-07-367243 22053108
12. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ, Um SJ, J Biol Chem 2010 285 18 29 10.1074/jbc.M109.065862 19880879
13. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, Kouzarides T, Nature 2009 461 819 822 10.1038/nature08448 19783980
14. Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and polycomb group gene Asx. Baskind HA, Na L, Ma Q, Patel MP, Geenen DL, Wang QT, PLoS One 2009 4 4750 10.1371/journal.pone.0004750 19270745
15. Mouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesis. Farber CR, Bennett BJ, Orozco L, Zou W, Lira A, Kostem E, Kang HM, Furlotte N, Berberyan A, Ghazalpour A, Suwanwela J, Drake TA, Eskin E, Wang QT, Teitelbaum SL, Lusis AJ, PLoS Genet 2011 7 1002038 10.1371/journal.pgen.1002038 21490954
16. Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}. Park UH, Yoon SK, Park T, Kim EJ, Um SJ, J Biol Chem 2011 286 1354 1363 10.1074/jbc.M110.177816 21047783
17. Identification and characterization of human CXXC10 gene in silico. Katoh M, Katoh M, Int J Oncol 2004 25 1193 1199 15375572
18. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, Beran M, Gilliland DG, Levine RL, Tefferi A, Leukemia 2011 25 1200 1202 10.1038/leu.2011.58 21455215
19. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL, Leukemia 2010 24 1656 1657 10.1038/leu.2010.144 20596031
20. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adélade J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ, Leukemia 2010 24 469 473 10.1038/leu.2009.218 19865112
21. Clinical effect of point mutations in myelodysplastic syndromes. Bejar R, Stevenson K, Abdel-Wahab O, Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL, N Engl J Med 2011 364 2496 2506 10.1056/NEJMoa1013343 21714648
22. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ, BMC Cancer 2010 10 401 407 10.1186/1471-2407-10-401 20678218
23. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska AM, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski, Br J Haematol 2010 150 83 87 20408841
24. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Szpurka H, Jankowska AM, Makishima H, Bodo J, Bejanyan N, Hsi ED, Sekeres MA, Maciejewski JP, Leuk Res 2010 34 969 973 10.1016/j.leukres.2010.02. 033 20334914
25. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S, Cancer Res 2010 70 447 452 10.1158/0008-5472.CAN-09-3783 20068184
26. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12 and TET2 in myeloproliferative neoplasms. Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A, Genes Chromosome Cancer 2012
27. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang L, Clark RE, Wainscoat JS, Leukemia 2010 24 1139 1145 10.1038/leu.2010.65 20410925
28. Mutations of ASXL1 gene in myeloproliferative neoplasms. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélade J, Rey J, Vainchenker W, Bernard OA, Chaffanet M, Vey N, Birnbaum D, Mozziconacci MJ, Leukemia 2009 23 2183 2186 10.1038/leu.2009.141 19609284
29. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF, Blood 2011 116 4086 4094
30. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Gelsi-Boyer V, Trouplin V, Roquain J, Adélade J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Br J Haematol 2010 151 365 375 10.1111/j.1365-2141.2010.08381.x 20880116
31. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in > 80% of patients with TET2 and EZH2 being of high prognostic relevance. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, Haferlach T, Schnittger S, Leukemia 2012 25 877 879
32. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP, Blood 2011 118 3932 3941 10.1182/blood-2010-10-311019 21828135
33. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Pratcorona M, Abbas S, Sanders M, Koenders J, Kavelaars F, Erpelinck-Verschueren C, Zeilemaker A, Lowenberg B, Valk P, Haematologica 2012 97 388 392 doi:10.3324 10.3324/haematol.2011.051532 22058207
34. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F, Clin Cancer Res 2010 16 2246 2256 10.1158/1078-0432.CCR-09-2112 20371679
35. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, Yan H, Chen FF, Chen HM, Chen Z, Jin J, Chen SJ, Blood 2011 118 5593 5603 10.1182/blood-2011-03-343988 21881046
36. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR, Haematologica 2011 96 1462 1469 10.3324/haematol.2011.045591 21712540
37. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A, J Clin Oncol 2011 29 2499 2506 10.1200/JCO.2010.33.4938 21576631
38. EZH2 mutational status predicts poor survival in myelofibrosis. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM, Blood 2011 118 5227 5234 10.1182/blood-2011-06-363424 21921040
39. Mutations affecting m RNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della-Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prebet T, Debotton S, VEY N, Morgan MA, Cross NCP, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M, Blood 2012
40. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrázek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Blood 2011 118 6920 6929 10.1182/blood-2011-08-368225 22031865
41. Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21. An Q, Wright SL, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Harrison CJ, Strefford JC, Haematologica 2009 94 1164 1169 10.3324/haematol.2008.002808 19586940
42. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BB, Nat Genet 2011 43 729 731 10.1038/ng.868 21706002
43. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Quesada V, Conde L, Villamor N, Ordá̃ez GR, Jares P, Bassaganyas L, Ramsay AJ, Be S, Pinyol M, Martínez-Trillos A, Lápez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Giné E, Hernández JM, González-Díaz M, Puente DA, Velasco G, Freije JM, Tubío JM, Royo R, Gelpí JL, Orozco M, Pisano DG, Zamora J, Vázquez M, Nat Genet 2011 44 47 52 10.1038/ng.1032 22158541
44. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Nature 2012 481 157 163 10.1038/nature10725 22237106
45. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11). Imamura T, Kakazu N, Hibi S, Morimoto A, Fukushima Y, Ijuin I, Hada S, Kitabayashi I, Abe T, Imashuku S, Genes Chromosomes Cancer 2003 36 413 419 10.1002/gcc.10172 12619166 (Pubitemid 36314525)
46. Alteration of enhancer of polycomb 1 at 10p11.2 is one of the genetic events leading to development of adult T-cell leukemia/lymphoma. Nakahata S, Saito Y, Hamasaki M, Hidaka T, Arai Y, Taki T, Taniwaki M, Morishita K, Genes Chromosomes Cancer 2009 48 768 776 10.1002/gcc.20681 19484761
47. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW, Blood 2010 115 38 46 10.1182/blood-2009-07-230698 19861679
48. ASXL1 mutations in primary and secondary myelofibrosis. Ricci C, Spinelli O, Salmoiraghi S, Finazzi G, Carobbio A, Rambaldi A, Br J Haematol 2012 156 404 407 10.1111/j.1365-2141.2011.08865.x 21923651
49. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A, J Clin Oncol 2011 29 392 397 10.1200/JCO.2010.32.2446 21149668
50. Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. Abstract 2811 ASH, December 2011. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Paoli C, Bosi A, Barosi G, Cross NCP, Vannucchi AM, Session: 634. Myeloproliferative Syndromes: Poster II
51. ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome. Abstract 416 ASH, December 2011. Schnittger S, Eder C, Alpermann T, Fasan A, Grossmann V, Alexander Kohlmann A, Kern W, Haferlach C, Haferlach T, Session: 611. Leukemias-Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Prognostic Biomarkers in Adult AML
52. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Löwenberg B, Valk PJ, Blood 2011 118 1069 1076 10.1182/blood-2011-02-334748 21596848
53. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD, Blood 2010 115 453 474 10.1182/blood-2009-07-235358 19880497